Edition:
United Kingdom

Jounce Therapeutics Inc (JNCE.OQ)

JNCE.OQ on NASDAQ Stock Exchange Global Select Market

12.52USD
15 Dec 2017
Change (% chg)

$-0.29 (-2.26%)
Prev Close
$12.81
Open
$12.81
Day's High
$13.05
Day's Low
$12.51
Volume
645,227
Avg. Vol
68,002
52-wk High
$29.29
52-wk Low
$11.05

Chart for

About

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on... (more)

Overall

Beta: --
Market Cap(Mil.): $554.71
Shares Outstanding(Mil.): 32.19
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Jounce Therapeutics reports Q3 loss $0.13/shr

* Jounce Therapeutics reports third quarter 2017 financial results

13 Nov 2017

BRIEF-Partner Fund Management L.P reports 5.4 pct passive stake in Jounce Therapeutics

* Partner Fund Management L.P reports 5.4 percent passive stake in Jounce Therapeutics Inc as of Sept 19, 2017 - SEC Filing Source text: (http://bit.ly/2ydfJp1) Further company coverage:

29 Sep 2017

BRIEF-Jounce Therapeutics reports Q2 loss of $0.11/shr

* Jounce Therapeutics reports second quarter 2017 financial results

09 Aug 2017

Earnings vs. Estimates